Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0518 · 1 trial · 2 indications
Area Under the Plasma Concentration-Time Curve and peak concentration
| Arm | Type | Description |
|---|---|---|
| Period 1 | EXPERIMENTAL | MK0518 |
| Period 2 | EXPERIMENTAL | famotidine + MK0518 |
| Period 3 | EXPERIMENTAL | omeprazole + MK0518 |
| Name | Type | Description |
|---|---|---|
| MK0518 (Raltegravir) | DRUG | 400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days. |
| famotidine | DRUG | Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518 |
| omeprazole | DRUG | 20 mg oral tablet of omeprazole, once daily for 5 days |
Inclusion Criteria: * Patient is Human immunodeficiency virus (HIV) positive * Patient is taking an MK0518 (Raltegravir) containing regimen * Patient has not had any changes to his/her antiviral regimen in the last 2 weeks * Patient who is of reproductive potential agrees to use an acceptable metho...
Top 20 of 28 competitors
MK0518 is an investigational small molecule being studied for the treatment of HIV infections and HIV-1 infection. It is being evaluated in HIV-infected patients, including those failing current antiretroviral therapies and treatment-naive patients, as part of combination therapy regimens.
MK0518 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in HIV-infected patients.
MK0518 is in Phase 3 clinical development. It has completed Phase 2 and Phase 3 trials, including a study comparing it to efavirenz in treatment-naive HIV-infected patients. The drug remains investigational and has not been approved by regulatory authorities.
MK0518 has been studied in several completed clinical trials, including NCT00100048 and NCT00105157 (Phase 2), NCT00369941 (Phase 3), and NCT01000818 (Phase 1). These trials evaluated its safety, efficacy, and pharmacokinetics in HIV-infected patients, with a total enrollment of 951 participants.
MK0518 is also known as raltegravir. In clinical trials, it is referred to by both names, such as in NCT01000818, which evaluates the effect of famotidine and omeprazole on MK0518 (Raltegravir) pharmacokinetics in HIV-infected patients.
MK0518 is a small molecule being studied for HIV treatment. Its specific molecular target has not been disclosed in the available information, so its mechanism of action is not described here. Clinical trials focus on its safety and efficacy in HIV-infected patients.